Abstract
Summary
Olanzapine is an atypical antipsychotic drugs, it is suitable for schizophrenia and other severe positive symptoms (for example: delusions, hallucinations, thought disorder, hostility and suspicion) and / or negative symptoms (such as: apathy acute and maintenance treatment, emotional and social withdrawal, poverty of speech) psychosis. In this report, we research and analyze the olanzapine, which used for manufacturing the olanzapine tablets.
LPI (LP Information)' newest research report, the “Olanzapine API Industry Forecast” looks at past sales and reviews total world Olanzapine API sales in 2022, providing a comprehensive analysis by region and market sector of projected Olanzapine API sales for 2023 through 2029. With Olanzapine API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Olanzapine API industry.
This Insight Report provides a comprehensive analysis of the global Olanzapine API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Olanzapine API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Olanzapine API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Olanzapine API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Olanzapine API.
The global Olanzapine API market size is projected to grow from US$ 188.8 million in 2022 to US$ 221.1 million in 2029; it is expected to grow at a CAGR of 221.1 from 2023 to 2029.
Global Olanzapine key players include Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Apotex Inc, Hansoh Pharmaceutical, etc. Global top five manufacturers hold a share over 85%.
North America is the largest market, with a share over 70%, followed by Asia, which has a share over 25%.
In terms of product, Patent is the largest segment, with a share about 55%. And in terms of application, the largest application is Olanzapine Tablets, followed by Daily Commodities, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Olanzapine API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Oral Grade
Injection Grade
Segmentation by application
Olanzapine Tablets
Olanzapine Injection
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dr. Reddy's Laboratories
Inke
Solara Active Pharma
Teva API
Cadila Pharmaceuticals
Anant Labs
Lavybens Pharma
Jubilant Generics
Venkatasai Life Sciences
Hangzhou Longshine Bio-tech
Neuland Lab
Key Questions Addressed in this Report
What is the 10-year outlook for the global Olanzapine API market?
What factors are driving Olanzapine API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Olanzapine API market opportunities vary by end market size?
How does Olanzapine API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Olanzapine API Industry Forecast” looks at past sales and reviews total world Olanzapine API sales in 2022, providing a comprehensive analysis by region and market sector of projected Olanzapine API sales for 2023 through 2029. With Olanzapine API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Olanzapine API industry.
This Insight Report provides a comprehensive analysis of the global Olanzapine API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Olanzapine API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Olanzapine API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Olanzapine API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Olanzapine API.
The global Olanzapine API market size is projected to grow from US$ 188.8 million in 2022 to US$ 221.1 million in 2029; it is expected to grow at a CAGR of 221.1 from 2023 to 2029.
Global Olanzapine key players include Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Apotex Inc, Hansoh Pharmaceutical, etc. Global top five manufacturers hold a share over 85%.
North America is the largest market, with a share over 70%, followed by Asia, which has a share over 25%.
In terms of product, Patent is the largest segment, with a share about 55%. And in terms of application, the largest application is Olanzapine Tablets, followed by Daily Commodities, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Olanzapine API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Oral Grade
Injection Grade
Segmentation by application
Olanzapine Tablets
Olanzapine Injection
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dr. Reddy's Laboratories
Inke
Solara Active Pharma
Teva API
Cadila Pharmaceuticals
Anant Labs
Lavybens Pharma
Jubilant Generics
Venkatasai Life Sciences
Hangzhou Longshine Bio-tech
Neuland Lab
Key Questions Addressed in this Report
What is the 10-year outlook for the global Olanzapine API market?
What factors are driving Olanzapine API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Olanzapine API market opportunities vary by end market size?
How does Olanzapine API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Olanzapine API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Olanzapine API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Olanzapine API by Country/Region, 2018, 2022 & 2029
2.2 Olanzapine API Segment by Type
2.2.1 Oral Grade
2.2.2 Injection Grade
2.3 Olanzapine API Sales by Type
2.3.1 Global Olanzapine API Sales Market Share by Type (2018-2023)
2.3.2 Global Olanzapine API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Olanzapine API Sale Price by Type (2018-2023)
2.4 Olanzapine API Segment by Application
2.4.1 Olanzapine Tablets
2.4.2 Olanzapine Injection
2.5 Olanzapine API Sales by Application
2.5.1 Global Olanzapine API Sale Market Share by Application (2018-2023)
2.5.2 Global Olanzapine API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Olanzapine API Sale Price by Application (2018-2023)
3 Global Olanzapine API by Company
3.1 Global Olanzapine API Breakdown Data by Company
3.1.1 Global Olanzapine API Annual Sales by Company (2018-2023)
3.1.2 Global Olanzapine API Sales Market Share by Company (2018-2023)
3.2 Global Olanzapine API Annual Revenue by Company (2018-2023)
3.2.1 Global Olanzapine API Revenue by Company (2018-2023)
3.2.2 Global Olanzapine API Revenue Market Share by Company (2018-2023)
3.3 Global Olanzapine API Sale Price by Company
3.4 Key Manufacturers Olanzapine API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Olanzapine API Product Location Distribution
3.4.2 Players Olanzapine API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Olanzapine API by Geographic Region
4.1 World Historic Olanzapine API Market Size by Geographic Region (2018-2023)
4.1.1 Global Olanzapine API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Olanzapine API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Olanzapine API Market Size by Country/Region (2018-2023)
4.2.1 Global Olanzapine API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Olanzapine API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Olanzapine API Sales Growth
4.4 APAC Olanzapine API Sales Growth
4.5 Europe Olanzapine API Sales Growth
4.6 Middle East & Africa Olanzapine API Sales Growth
5 Americas
5.1 Americas Olanzapine API Sales by Country
5.1.1 Americas Olanzapine API Sales by Country (2018-2023)
5.1.2 Americas Olanzapine API Revenue by Country (2018-2023)
5.2 Americas Olanzapine API Sales by Type
5.3 Americas Olanzapine API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Olanzapine API Sales by Region
6.1.1 APAC Olanzapine API Sales by Region (2018-2023)
6.1.2 APAC Olanzapine API Revenue by Region (2018-2023)
6.2 APAC Olanzapine API Sales by Type
6.3 APAC Olanzapine API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Olanzapine API by Country
7.1.1 Europe Olanzapine API Sales by Country (2018-2023)
7.1.2 Europe Olanzapine API Revenue by Country (2018-2023)
7.2 Europe Olanzapine API Sales by Type
7.3 Europe Olanzapine API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Olanzapine API by Country
8.1.1 Middle East & Africa Olanzapine API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Olanzapine API Revenue by Country (2018-2023)
8.2 Middle East & Africa Olanzapine API Sales by Type
8.3 Middle East & Africa Olanzapine API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Olanzapine API
10.3 Manufacturing Process Analysis of Olanzapine API
10.4 Industry Chain Structure of Olanzapine API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Olanzapine API Distributors
11.3 Olanzapine API Customer
12 World Forecast Review for Olanzapine API by Geographic Region
12.1 Global Olanzapine API Market Size Forecast by Region
12.1.1 Global Olanzapine API Forecast by Region (2024-2029)
12.1.2 Global Olanzapine API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Olanzapine API Forecast by Type
12.7 Global Olanzapine API Forecast by Application
13 Key Players Analysis
13.1 Dr. Reddy's Laboratories
13.1.1 Dr. Reddy's Laboratories Company Information
13.1.2 Dr. Reddy's Laboratories Olanzapine API Product Portfolios and Specifications
13.1.3 Dr. Reddy's Laboratories Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Dr. Reddy's Laboratories Main Business Overview
13.1.5 Dr. Reddy's Laboratories Latest Developments
13.2 Inke
13.2.1 Inke Company Information
13.2.2 Inke Olanzapine API Product Portfolios and Specifications
13.2.3 Inke Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Inke Main Business Overview
13.2.5 Inke Latest Developments
13.3 Solara Active Pharma
13.3.1 Solara Active Pharma Company Information
13.3.2 Solara Active Pharma Olanzapine API Product Portfolios and Specifications
13.3.3 Solara Active Pharma Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Solara Active Pharma Main Business Overview
13.3.5 Solara Active Pharma Latest Developments
13.4 Teva API
13.4.1 Teva API Company Information
13.4.2 Teva API Olanzapine API Product Portfolios and Specifications
13.4.3 Teva API Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Teva API Main Business Overview
13.4.5 Teva API Latest Developments
13.5 Cadila Pharmaceuticals
13.5.1 Cadila Pharmaceuticals Company Information
13.5.2 Cadila Pharmaceuticals Olanzapine API Product Portfolios and Specifications
13.5.3 Cadila Pharmaceuticals Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Cadila Pharmaceuticals Main Business Overview
13.5.5 Cadila Pharmaceuticals Latest Developments
13.6 Anant Labs
13.6.1 Anant Labs Company Information
13.6.2 Anant Labs Olanzapine API Product Portfolios and Specifications
13.6.3 Anant Labs Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Anant Labs Main Business Overview
13.6.5 Anant Labs Latest Developments
13.7 Lavybens Pharma
13.7.1 Lavybens Pharma Company Information
13.7.2 Lavybens Pharma Olanzapine API Product Portfolios and Specifications
13.7.3 Lavybens Pharma Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Lavybens Pharma Main Business Overview
13.7.5 Lavybens Pharma Latest Developments
13.8 Jubilant Generics
13.8.1 Jubilant Generics Company Information
13.8.2 Jubilant Generics Olanzapine API Product Portfolios and Specifications
13.8.3 Jubilant Generics Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Jubilant Generics Main Business Overview
13.8.5 Jubilant Generics Latest Developments
13.9 Venkatasai Life Sciences
13.9.1 Venkatasai Life Sciences Company Information
13.9.2 Venkatasai Life Sciences Olanzapine API Product Portfolios and Specifications
13.9.3 Venkatasai Life Sciences Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Venkatasai Life Sciences Main Business Overview
13.9.5 Venkatasai Life Sciences Latest Developments
13.10 Hangzhou Longshine Bio-tech
13.10.1 Hangzhou Longshine Bio-tech Company Information
13.10.2 Hangzhou Longshine Bio-tech Olanzapine API Product Portfolios and Specifications
13.10.3 Hangzhou Longshine Bio-tech Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Hangzhou Longshine Bio-tech Main Business Overview
13.10.5 Hangzhou Longshine Bio-tech Latest Developments
13.11 Neuland Lab
13.11.1 Neuland Lab Company Information
13.11.2 Neuland Lab Olanzapine API Product Portfolios and Specifications
13.11.3 Neuland Lab Olanzapine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Neuland Lab Main Business Overview
13.11.5 Neuland Lab Latest Developments
14 Research Findings and Conclusion